Asset Management One Co. Ltd. Has $95.09 Million Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Asset Management One Co. Ltd. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 5.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 191,998 shares of the medical equipment provider's stock after purchasing an additional 9,439 shares during the period. Asset Management One Co. Ltd. owned approximately 0.05% of Intuitive Surgical worth $95,091,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Brighton Jones LLC raised its holdings in Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after purchasing an additional 731 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its stake in shares of Intuitive Surgical by 0.5% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock valued at $99,678,000 after acquiring an additional 883 shares during the last quarter. Wealthspire Advisors LLC raised its stake in Intuitive Surgical by 28.6% in the 4th quarter. Wealthspire Advisors LLC now owns 1,645 shares of the medical equipment provider's stock valued at $859,000 after purchasing an additional 366 shares during the last quarter. MONECO Advisors LLC lifted its holdings in Intuitive Surgical by 8.1% in the 4th quarter. MONECO Advisors LLC now owns 1,129 shares of the medical equipment provider's stock valued at $589,000 after purchasing an additional 85 shares in the last quarter. Finally, World Equity Group Inc. boosted its stake in shares of Intuitive Surgical by 22.8% during the 4th quarter. World Equity Group Inc. now owns 512 shares of the medical equipment provider's stock worth $267,000 after purchasing an additional 95 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded down $1.45 during trading hours on Wednesday, hitting $521.63. The stock had a trading volume of 1,166,866 shares, compared to its average volume of 1,673,765. The stock's fifty day simple moving average is $529.22 and its 200 day simple moving average is $536.97. The firm has a market capitalization of $186.96 billion, a price-to-earnings ratio of 76.49, a PEG ratio of 5.46 and a beta of 1.67. Intuitive Surgical, Inc. has a 1-year low of $413.82 and a 1-year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The business had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. During the same period in the previous year, the business earned $1.50 earnings per share. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ISRG. Robert W. Baird reduced their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Erste Group Bank raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Thursday, June 5th. Truist Financial cut their price objective on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft downgraded Intuitive Surgical from a "hold" rating to a "sell" rating and lowered their target price for the company from $515.00 to $440.00 in a research note on Monday, June 9th. Finally, Evercore ISI dropped their target price on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a research report on Wednesday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and a consensus target price of $588.95.

Insiders Place Their Bets

In related news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president now owns 907 shares of the company's stock, valued at $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Robert Desantis sold 188 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $515.91, for a total transaction of $96,991.08. Following the completion of the sale, the executive vice president now owns 5,224 shares in the company, valued at approximately $2,695,113.84. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,998 shares of company stock worth $2,611,577 over the last ninety days. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.